New Long-Term Data from the CHRYSALIS Study Show mPFS Not Reached after 33.6 Months of Follow-Up with 1L RYBREVANT and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced NSCLC

“Advanced NSCLC and EGFR-mutated lung cancer has a five-year survival rate of less than 20 percent, underscoring an urgent need for more targeted treatment options, especially in earlier lines of therapy,” said Se-Hoon Lee**, M.D., Ph.D., professor of medicine at the Samsung Medical Center and Sungkyunkwan University School of Medicine, and presenting author. “These long-term data for amivantamab and lazertinib introduce the potential for this combination therapy to be used as first-line treatment for this patient population.”